Intellia Hits Pause On Phase III Nex-z Studies After Second Liver Enzyme Event

 
• By Alaric DeArment
  
Intellia paused screening and dosing in its Phase III transthyretin amyloidosis trials of gene-edited medicine nex-z. (Shutterstock)

More from Gene Therapies

More from Advanced Therapies